# Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

> **NCT01059825** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 375 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo to Ertugliflozin
- **DRUG:** Ertugliflozin 1 mg
- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 25 mg
- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo to Sitagliptin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01059825
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-24
- **Primary completion:** 2011-01-20
- **Final completion:** 2011-01-20
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059825, "Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01059825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*